Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SKYE
SKYE BIOSCIENCE, INC.
NASDAQ
$1.77
▼ DOWN 8.97% (-0.17)

KEY STATISTICS

Market Cap$7.80 M
52w High$39.92
52w Low$1.76
Dividend Yield—
Frequency—
P/E-1.40
Volume77.97K
Shares Out.4.39M

COMPANY

LEADERSHIP

Punit S. Dhillon
CHIEF EXECUTIVE
Punit S. Dhillon

COMPENSATION 2026

Salary$610,000
Stock Awards$0
Incentive Plan Pay$219,600
All Other Comp.$0
Total$1,361,831

ABOUT

SECTOR
Healthcare
WENT PUBLIC
January 6, 2015
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
2

PRICE TARGET

Target High$21.00
Target Low$2.00
Target Median$15.00
Target Consensus$12.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.—
NOV
9
MON

SPLIT RECORD

DATETYPERATIO
2026-08-24Reverse1:8
2023-09-08Reverse1:250

PRICE

$1.77 ▼ DOWN 8.97% (−$0.17)
OVERLAYS
$1.80$1.87$1.959:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM1.77

About Skye Bioscience, Inc.

https://skyebioscience.com ↗

Skye Bioscience, Inc. is a San Diego-based biopharmaceutical company developing cannabinoid-based treatments for infectious and eye diseases, with lead candidates SBI-100 in Phase I and SBI-200 in preclinical trials.

INDUSTRY

Biotechnology

A PRODUCT SKYE BIOSCIENCE, INC. IS KNOWN FOR

Nimacimab
Nimacimab

Nimacimab, Skye Bioscience's lead peripherally-restricted CB1 inhibitor antibody in Phase 2a trials, is being developed for obesity treatment, with a focus on combination therapy with semaglutide.

COMPETITORS

COMPETITOR
AMGN COMPARE
GKOS COMPARE
LLY COMPARE
NVO COMPARE
VKTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
11
LISTED HERE
1
RANKED BY POSITION SIZE
VTS.AX
0.00% · 561.8K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
100.00%
HOLDERS
80
TOP 12 OF 80 · RANKED BY POSITION SIZE
5am Venture Management, LLC
9.7M sh · $6.71M
Versant Venture Management, LLC
2.0M sh · $1.39M
Baker Bros. Advisors LP
1.6M sh · $1.09M
Schonfeld Strategic Advisors LLC
1.2M sh · $4.67M
Blackrock Inc.
1.1M sh · $8.96M
Vanguard Group Inc
882.8K sh · $3.47M
Ensign Peak Advisors, Inc
767.3K sh · $3.02M
Cvi Holdings, LLC
679.7K sh · $5.44M
Sphera Funds Management Ltd.
678.9K sh · $470.7K
Driehaus Capital Management LLC
620.4K sh · $2.44M
Alyeska Investment Group, L.P.
456.2K sh · $1.79M
Millennium Management LLC
402.4K sh · $1.58M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
DIRECTOR, 10 PERCENT OWNER:
Schwab Andrew J.
Sale · 10.3K shares
2026-08-19
★
DIRECTOR, 10 PERCENT OWNER:
Schwab Andrew J.
Sale · 1.2K shares
2026-08-20
★
10 PERCENT OWNER
5AM Partners VII, LLC
Sale · 57.5K shares
2026-08-19
★
10 PERCENT OWNER
5AM Partners VII, LLC
Sale · 6.5K shares
2026-08-20

SECTORS PEERS

PEERPRICE
XFOR$4.04COMPARE
INMB$2.33COMPARE
XLO$9.00COMPARE
ALGS$6.91COMPARE
BRNS$0.75COMPARE
PDSB$0.21COMPARE